To elucidate how the CD39/CD73/A2AR pathway and PD-1/PD-L1 axis interact in immunosuppressive signaling in RCC, we need to study the mechanisms underlying anti-tumor immunity, including immune cell infiltration and angiogenesis. This evidence concerns the gene ENTPD1 and renal cell carcinoma.